Dynamics of cytokine profile parameters during olokizumab therapy: Results of a single-center randomized controlled trial

Authors:

Abstract
The aim – to evaluate the effect of olokizumab (OKZ) on the levels of proand anti-inflammatory cytokines, chemokines, and growth factors in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included; 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents (BAs). At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio into one of three groups: Group 1 received treatment with sDMARDs+OKZ 64 mg subcutaneously once every 4 weeks (4N) (n=49); Group 2 – sDMARDs+OKZ 64 mg subcutaneously 4N + psychopharmacotherapy (PPT) (n=51); Group 3 – sDMARDs+PPT (n=25). The study duration was 24 weeks. The concentration of 27 cytokines in the serum was measured using multiplex xMAP technology on a Bio-Plex array system analyzer (Bio-Rad, USA). Results . After 12 weeks of OKZ therapy, a significant decrease in the level of proinflammatory cytokines – interleukin (IL) 2; anti-inflammatory cytokines – IL-4, IL-10, IL-13, IL-1 receptor antagonist (IL-1Ra); chemokines – macrophage inflammatory protein 1α (MIP-1α), interferon γ-stimulated protein 10 (IP-10), IL-8; growth factors – IL-7, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF-bb); an increase in the level of anti-inflammatory cytokines – IL-5, IL-9, Eotaxin and tumor necrosis factor α (TNF-α); after 24 weeks of therapy – a decrease in the level of pro-inflammatory cytokines – IL-2, IL-15; anti-inflammatory cytokines – IL-4, IL-13, IL-1Ra; chemokines – monocyte chemotactic protein-1 (MCP-1), MIP-1α, IL-8; growth factors – IL-7, PDGF-bb; increased levels of Eotaxin and TNF-α. Conclusion. The use of OKZ is accompanied by a decrease in the level of proinflammatory cytokines, chemokines, and growth factors, and an increase in the content of TNF-α.

This publication has 62 references indexed in Scilit: